DDrare: Database of Drug Development for Rare Diseases

Searched query = "Wilson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 64CuCl2; ALXN1840; Acetate; Artamin 150 mg; Artamin 250 mg; BIS-CHOLINE TETRATHIOMOLYBDATE; Bis-Choline Tetrathiomolybdate; Bis-choline TETRATHIOMOLYBDATE; Bupropion; Bupropion Hydrochloride; COPPER (64CU) CHLORIDE; Celecoxib; Chloride; Choline; Copper; Cuprior; Cuprior 150 mg film-coated tablets; Cuprior 150mg film-coated tablets; D-penicillamine; D-penicillamine 150mg; D-penicillamine 250 mg; DMPS; DMSA; Galactose; Gold; Metalcaptase® 150 mg gastro-resistant tablet; Metalcaptase® 300 mg gastro-resistant tablet; NPC-02; Nitrogen; None; Once a day Trientine; PEMINE - 150 MG CAPSULE RIGIDE 50 CAPSULE; PENICILLAMINE; Penicillamine; Procedure: Fibroscan; Procedure: Functional hepatic nitrogen clearance; Procedure: Liver biopsy; Procedure: Ultrasound; SoC Therapy; Standard of Care Medications; TETA; TETA 4HCL; TETA 4HCl; TETA.4HCI; TETA.4HCl; TRIENTINE DIHYDROCHLORIDE; Tetrathiomolybdate; Trientine; Trientine dihydrochloride; Trientine dihydrochloride 300mg capsules; Trientine tetrahydrochloride; WTX101; Wilzin; ZINC ACETATE DIHYDRATE; ZINC GLUCONATE; Zinc; Zinc acetate; Zinc gluconate; Zink Natur-Drogeriet

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04526210 (ClinicalTrials.gov)	August 2020	19/8/2020	Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants	A Phase 1, Randomized, 2-Period, 2-Sequence, Cross-over Study to Determine the Effect of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants	Wilson Disease	Drug: ALXN1840;Drug: Bupropion Hydrochloride	Alexion Pharmaceuticals	NULL	Enrolling by invitation	18 Years	50 Years	All	38	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04526210
(ClinicalTrials.gov)

August 2020

19/8/2020

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

A Phase 1, Randomized, 2-Period, 2-Sequence, Cross-over Study to Determine the Effect of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Wilson Disease

Drug: ALXN1840;Drug: Bupropion Hydrochloride

Alexion Pharmaceuticals

NULL

Enrolling by invitation

18 Years

50 Years

All

Phase 1

United States